Emtora Biosciences

About:

Emtora Biosciences is a life science company that commercializes a new formulation of an immunosuppressant as a prostate cancer drug.

Website: https://emtorabio.com/

Top Investors: Cancer Prevention and Research Institute of Texas, UT Horizon Fund

Description:

Emtora Biosciences is a life science company that commercializes a new formulation of an immunosuppressant as a prostate cancer drug. The company developing a novel formulation of rapamycin, eRapa for use in preventing the onset and recurrence of cancer. It manufactures a drug to slow the aging process and its efficacy in treating age-related diseases. The eRapa is the only pharmaceutical agent to demonstrate significantly increased healthspan and lifespan in rodent models, and Science, Nature, and Time magazines proclaimed the discovery of a special formulation of rapamycin to extend one’s life and health span among the most significant and exciting scientific breakthroughs of 2009.

Total Funding Amount:

$23.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Antonio, Texas, United States

Founded Date:

2012-01-01

Founders:

George Fillis

Number of Employees:

1-10

Last Funding Date:

2022-08-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai